Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity

Hepatocarcinoma is one of the most prevalent gastroenterological cancers in the world with less effective therapy. As an oncofetal antigen and diagnostic marker for liver cancer, alpha-fetoprotein (AFP) possesses a variety of biological functions. Except for its diagnosis in liver cancer, AFP has be...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoping Wang, Qiaoxia Wang
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Canadian Journal of Gastroenterology and Hepatology
Online Access:http://dx.doi.org/10.1155/2018/9049252
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832554369792344064
author Xiaoping Wang
Qiaoxia Wang
author_facet Xiaoping Wang
Qiaoxia Wang
author_sort Xiaoping Wang
collection DOAJ
description Hepatocarcinoma is one of the most prevalent gastroenterological cancers in the world with less effective therapy. As an oncofetal antigen and diagnostic marker for liver cancer, alpha-fetoprotein (AFP) possesses a variety of biological functions. Except for its diagnosis in liver cancer, AFP has become a target for liver cancer immunotherapy. Although the immunogenicity of AFP is weak and it could induce the immune escapes through inhibiting the function of dendritic cells, natural killer cells, and T lymphocytes, AFP has attracted more attention in liver cancer immunotherapy. By in vitro modification, the immunogenicity and immune response of AFP could be enhanced. AFP-modified immune cell vaccine or peptide vaccine has displayed the specific antitumor immunity against AFP-positive tumor cells and laid a better foundation for the immunotherapy of liver cancer.
format Article
id doaj-art-7fc4fdaea07d4562a41320d9073660e7
institution Kabale University
issn 2291-2789
2291-2797
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Canadian Journal of Gastroenterology and Hepatology
spelling doaj-art-7fc4fdaea07d4562a41320d9073660e72025-02-03T05:51:40ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972018-01-01201810.1155/2018/90492529049252Alpha-Fetoprotein and Hepatocellular Carcinoma ImmunityXiaoping Wang0Qiaoxia Wang1Laboratory of Molecular Biology & Pathology, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, ChinaDepartment of Infectious Diseases, Xi’an Central Hospital, Xi’an, Shaanxi 710000, ChinaHepatocarcinoma is one of the most prevalent gastroenterological cancers in the world with less effective therapy. As an oncofetal antigen and diagnostic marker for liver cancer, alpha-fetoprotein (AFP) possesses a variety of biological functions. Except for its diagnosis in liver cancer, AFP has become a target for liver cancer immunotherapy. Although the immunogenicity of AFP is weak and it could induce the immune escapes through inhibiting the function of dendritic cells, natural killer cells, and T lymphocytes, AFP has attracted more attention in liver cancer immunotherapy. By in vitro modification, the immunogenicity and immune response of AFP could be enhanced. AFP-modified immune cell vaccine or peptide vaccine has displayed the specific antitumor immunity against AFP-positive tumor cells and laid a better foundation for the immunotherapy of liver cancer.http://dx.doi.org/10.1155/2018/9049252
spellingShingle Xiaoping Wang
Qiaoxia Wang
Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity
Canadian Journal of Gastroenterology and Hepatology
title Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity
title_full Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity
title_fullStr Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity
title_full_unstemmed Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity
title_short Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity
title_sort alpha fetoprotein and hepatocellular carcinoma immunity
url http://dx.doi.org/10.1155/2018/9049252
work_keys_str_mv AT xiaopingwang alphafetoproteinandhepatocellularcarcinomaimmunity
AT qiaoxiawang alphafetoproteinandhepatocellularcarcinomaimmunity